PAM
MRSN

Panagora Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Panagora Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,818
Closed -$128K – 1180
2025
Q1 		$128K Buy
14,818
+5,231
+55% +$80.7K ﹤0.01% 1069
2024
Q4 		$343K Buy
9,587
+259
+3% +$13.4K ﹤0.01% 922
2024
Q3 		$441K Sell
9,328
-121
-1% -$5.34K ﹤0.01% 959
2024
Q2 		$475K Buy
9,449
+7
+0.1% +$506 ﹤0.01% 927
2024
Q1 		$1.06M Sell
9,442
-613
-6% -$60.9K 0.01% 778
2023
Q4 		$583K Sell
10,055
-17
-0.2% -$684 ﹤0.01% 955
2023
Q3 		$320K Sell
10,072
-788
-7% -$37.5K ﹤0.01% 1063
2023
Q2 		$893K Buy
10,860
+2,212
+26% +$324K 0.01% 821
2023
Q1 		$889K Buy
8,648
+1,009
+13% +$142K 0.01% 882
2022
Q4 		$1.12M Buy
7,639
+168
+2% +$28.4K 0.01% 845
2022
Q3 		$1.26M Buy
+7,471
New +$1.21M 0.01% 765
2021
Q3 		– Sell
-9
Closed -$3K – 2120
2021
Q2 		$3K Sell
9
-710
-99% -$269K ﹤0.01% 2578
2021
Q1 		$291K Sell
719
-47
-6% -$22.8K ﹤0.01% 1577
2020
Q4 		$508K Buy
766
+47
+7% +$26.1K ﹤0.01% 1223
2020
Q3 		$335K Sell
719
-3,727
-84% -$1.88M ﹤0.01% 1308
2020
Q2 		$2.6M Sell
4,446
-2,124
-32% -$725K 0.02% 579
2020
Q1 		$957K Buy
6,570
+1,604
+32% +$280K 0.01% 862
2019
Q4 		$711K Sell
4,966
-6,556
-57% -$479K ﹤0.01% 1178
2019
Q3 		$455K Buy
11,522
+7,599
+194% +$553K ﹤0.01% 1320
2019
Q2 		$397K Buy
+3,923
New +$462K ﹤0.01% 1510

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Panagora Asset Management's MRSN Position: Q2 2025 in Review

Panagora Asset Management sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 14,818 shares — an estimated $128K sold.

Panagora Asset Management first reported a position in MRSN in Q2 2019 and held it in 20 quarters. The position peaked at $2.6M in Q2 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Panagora Asset Management reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Panagora Asset Management sold 14,818 Mersana Therapeutics shares in Q2 2025, an estimated $128K.
  • Panagora Asset Management first reported a position in Mersana Therapeutics in Q2 2019 and held it in 20 quarters.
  • Panagora Asset Management's Mersana Therapeutics position peaked at $2.6M in Q2 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Panagora Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.